EVALUATION OF GM-CSF FOR TREATMENT OF CHRONIC HCV
$0M01FY2001RRNIH
Virginia Commonwealth University, Richmond VA
Investigators
Linked publications & trials
Paper 38778481Paper 38225212Paper 33023400Paper 28103725Paper 25783671Paper 25714579Paper 25264599Paper 25248382Paper 24119188Paper 23686698Paper 23515411Paper 23510278Paper 23329066Paper 23315028Paper 23311611Paper 23280525Paper 22917126Paper 22688849Paper 22611049Paper 22532269Paper 22521357Paper 22466024Paper 22458586Paper 22434223Paper 22359532Paper 22349810Paper 22343513Paper 22309991Paper 22228833Paper 22213086Paper 22197855Paper 22103921Paper 22103814Paper 22100576Paper 22045670Paper 22045667Paper 22036053Paper 22030902Paper 21953442Paper 21946897Paper 21931376Paper 21883917Paper 21871763Paper 21856199Paper 21782771Paper 21760886Paper 21757974Paper 21733508Paper 21699796Paper 21557024Paper 21556038Paper 21554994Paper 21526398Paper 21521847Paper 21520194Paper 21515002Paper 21480316Paper 21447728Paper 21440548Paper 21423719Paper 21406504Paper 21376050Paper 21374690Paper 21362113Paper 21335007Paper 21319198Paper 21274866Paper 21224253Paper 21208761Paper 21206486Paper 21176217Paper 21172393Paper 21139575Paper 21136163Paper 21129375Paper 21126792Paper 21114621Paper 21083592Paper 20728569Paper 20684021Paper 20675691Paper 20672296Paper 20648476Paper 20648472Paper 20564351Paper 20427778Paper 20372110Paper 20362695Paper 20359725Paper 20351741Paper 20332289Paper 20301112Paper 20211180Paper 20178797Paper 20132120Paper 20132119Paper 20132118Paper 20101752Paper 20070284Paper 20044810
Abstract
To determine if the combination of GM-CSF with interferon-a-2b is more effective at achieving either biochemical, histologic and/or virologic response in patients with chronic HCV than is interferon alone. To define the side effects of GM-CSF when utilized in combination with interferon or as single agent therapy for treatment of chronic HCV.
View original record on NIH RePORTER →